Drugs / Recombinant Thyrotropin Alfa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06440850 Background | Jul 2024 → Nov 2026 expected | thyroid gland follicular carcinoma, thyroid gland papillary carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT00085293 Background | May 2004 → Jan 2014 | thyroid gland follicular carcinoma, thyroid gland papillary carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant thyrotropin alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00085293 ↗ |
| Route | Intramuscular | “Given IM” NCT06440850 ↗ |